Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Industry

9 Dec 2021

Mydecine Secures Financing and Provides Company Update

Mydecine Secures Financing and Provides Company Update....

By Jason Najum

Industry

9 Dec 2021

GH Research Update: Financials, Business Update, and Trial Results

Now we have news of $280 million in cash on hand, and successful outcomes in a Phase 2 clinical trial using 5-MeO-DMT for treatment-resistant depression....

By Jason Najum

Law & Politics

7 Dec 2021

Toronto Board of Health Votes to Decriminalize Drugs

Toronto’s Board of Health voted unanimously to request that the federal government give Toronto the right to decriminalize the possession of small amounts of drugs....

By Jason Najum

Don’t Miss

6 Dec 2021

News You Might Have Missed: December 6, 2021

Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

1 Dec 2021

Cybin Gets FDA Approval For New Phase 2 Trial

Following up on their recent run of solid news (led by very positive results from their new CYB-003 compound), Cybin has just announced that the FDA has authorized a Phase...

By Jason Najum

Science

1 Dec 2021

New Study Shows Mushrooms Can Reverse Alcohol Brain Damage

A new study released last week shows that psilocybin, the psychoactive ingredient in magic mushrooms, can change the part of the brain that controls alcoholism or alcohol cravings....

By Jason Najum

Law & Politics

30 Nov 2021

City of Toronto to Vote on Decriminalization

In a report released yesterday, Toronto’s Medical Officer of Health Dr....

By Jason Najum

Industry

29 Nov 2021

ATAI Increases Ownership in COMPASS Pathways

Atai Life Sciences, the psychedelic medicine industry’s leader by market cap, has announced the purchase of another 619,095 Compass Pathways shares....

By Jason Najum

Industry

26 Nov 2021

Seelos Raises $20M, Acquires Ketamine Tech, and Announces New Drug

This week Seelos released several pieces of important news: they raised $20 million in capital, acquired a worldwide license for sublingual ketamine delivery technology, and announced the evaluation of a...

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.